




# Johnson & Johnson's life-enhancing innovation & operational excellence are founded in:


## OUR PURPOSE

We blend , science and **ingenuity** to profoundly change the trajectory of health for humanity

## OUR PEOPLE


Dedicated employees who help our products serve more than **1 billion people worldwide** each day

## OUR FINANCIAL STRENGTH

 **Largest, most diversified** healthcare products company in the world

 **Strong global positions** across multiple franchises and therapeutic areas

 **Robust and broadly based** innovation pipeline

 **Consistent and solid** financial returns

## OUR PATH FORWARD

 **Enterprise**

Focus on achieving near-term financial targets, maintaining high quality standards and continuing to invest for long-term value creation

 **Pharmaceutical**

Expect to deliver topline growth in the near- and long-term through maximizing current portfolio value, uptake from new launches and continued R&D investment

 **MedTech**

Maximize commercial opportunity for recently launched innovations, advance the Abiomed portfolio and prioritize investment in higher-growth market segments

 **Consumer Health**

Deliver science-backed innovation and digital, consumer-centric solutions while creating a successful new standalone industry leader



## Key Industry Recognitions & Accolades

**FORTUNE** **20<sup>th</sup> Consecutive Year** as a Top 50 All-Star on The World's Most Admired Companies List, **#1** in Pharmaceutical Category in 2022

**WSJ** **#9** The Best-Managed Companies of 2022


**Forbes** **4<sup>th</sup> Consecutive Year** on the Best Employers for Diversity in 2022


**Gartner** **#4** Supply Chain Top 25 for 2022

**FAST COMPANY** J&J MedTech Earned a Spot in the **Top 10** Most Innovative Health Companies of 2022

## Environmental, Social & Governance

**21** Ambitious Health for Humanity 2025 goals addressing pandemics and epidemics, global health equity, our people, planet and partners

 Ranked **#2** in the Access to Medicine Index, marking the sixth consecutive time featured as a top three performer

 Recognized in 2022 with a CDP Climate Change A List rating for the fifth consecutive year

**MSCI**  Achieved an MSCI "A" ESG Rating in 2022

## Value Creation Initiatives

### R&D Investment and Product Innovation

 **#2** Ranked Pharm company in 2022 R&D investment<sup>1</sup>

 **6** New Pharm product approvals during 2022

 **>20** MedTech pipeline programs with eNPV greater than \$100MM

<sup>1</sup> Per Capital IQ

<sup>2</sup> Strategic partnerships, acquisitions & licensing related to 2022 activity

### Strategic Partnerships, Acquisitions & Licensing<sup>2</sup>

**81** Innovation Deals

**20** New Equity Investments

**8** Acquisitions and Noteworthy Licensing Agreements



# Delivering Long-Term Value for our Stakeholders

## Our Capital Allocation Priorities

**Fuel** internal growth opportunities through R&D investment

**Pursue** value creating mergers, acquisitions, partnerships & licensing agreements

**Deliver** competitive dividend

**Execute** share repurchase programs with excess capital

✓ = Achieved in 2022

### Free Cash Flow<sup>1</sup>

~\$96B

Total free cash flow over the past 5 years<sup>8</sup>

>60%

5-Year free cash flow returned to shareholders<sup>7,8</sup>

## A Strong, Consistent, Sustainable Business

~5% Operational sales growth<sup>2</sup>

~8% Adjusted EPS growth<sup>3</sup>

Compound annual growth over the last 20 years

12.7%

10-Year total return to shareholders

~25%

of sales come from products launched in the past 5 years

>60

Consecutive years of dividend increases<sup>4</sup>

>70%

of sales come from #1 or #2 global market share position


AAA

Rated Balance Sheet

## Sales by Business Segment

Dollars in Billions

Percent Change vs. 2021



	Reported	Operational <sup>2</sup>	Adjusted Operational <sup>5</sup>
Consumer Health	-0.5%	3.6%	3.9%
Pharmaceutical	1.7%	6.7%	6.8%
MedTech	1.4%	6.2%	6.1%
Worldwide	1.3%	6.1%	6.2%


Note: All data included is based on 2022 full year, unless noted otherwise. Reference Non-GAAP reconciliation schedules in the Investors section at Investor.jnj.com. Sales figures may not sum to total due to rounding. <sup>1</sup> Non-GAAP measure; defined as operating cash flow less capital spending. <sup>2</sup> Non-GAAP measure; excludes the impact of translational currency. <sup>3</sup> Non-GAAP measure; excludes intangible amortization expense, and special items. <sup>4</sup> Includes dividend declared in April 2023. <sup>5</sup> Non-GAAP measure; excludes the net impact of acquisitions and divestitures and translational currency <sup>6</sup> SIMPONI includes SIMPONI and SIMPONI ARIA <sup>7</sup> Includes impact of dividend payments and share repurchases <sup>8</sup> Representative of 2018 - 2022

## 29 Platforms / Products >\$1 Billion in Annual Sales<sup>6</sup>

Consumer Health (4)	Pharmaceutical (14)	MedTech (11)
Neutrogena	Stelara <sup>®</sup> (ustekinumab), DARZALEX (daratumumab), imbruvica <sup>®</sup> (ibrutinib)	Knees, Hips, Spine
LISTERINE	INVEGA SUSTENNA, Remicade <sup>®</sup> (infliximab), Xarelto (rivaroxaban)	Trauma, Endocutters
Johnson's	Zytiga (abiraterone acetate), Simponi <sup>®</sup> (golimumab), Tremfya (guselkumab)	Biosurgery, Energy
TYLENOL	Symtuza <sup>®</sup> , Erleada (apalutamide), Upravi (sellekpap)	Wound Closure, Electrophysiology
	Opsumit (macitentan), EDURANT (ripivirine) tablets	Contact Lenses, Surgical Vision


## Sales by Geographic Area

Dollars in Billions



## Net Earnings

Dollars in Billions



## Earnings Per Share

Dollars

